局限性前列腺癌的立体定向放疗

doi:10.3760/cma.j.cn371439-20200802-00060

摘要/Abstract

摘要：

体外放疗是治疗局限性前列腺癌的主要手段之一,目前临床上普遍采用的是常规分割放疗,但有研究表明前列腺癌对超低分割放疗即立体定向放疗(SBRT)也具有高度敏感性,增加放疗剂量可以明显提高肿瘤局部控制率。根据目前的研究来看,在局限性前列腺癌放疗效果方面,SBRT的治疗效果不亚于常规分割放疗;在放射毒性方面,SBRT在治疗后较传统分割放疗近期毒性更明显,但远期毒性并无明显差异。SBRT能够为患者提供更多的方便,且医疗成本更低,有较大的临床应用前景。

关键词: 前列腺肿瘤, 放射外科手术, 放射疗法

Abstract:

External-beam radiotherapy is one of the principle treatment options for localized prostate cancer. Conventionally fractionated radiotherapy is widely used in clinical practice. Studies have shown that prostate cancer is highly sensitive to hypofractionated radiotherapy, also known as stereotactic body radiotherapy (SBRT), and increasing radiotherapy dose can significantly improve the local control rate of tumor. A number of recently completed researches have shown that SBRT is as effective as conventionally fractionated radiotherapy. In terms of radiation toxicity, the short-term toxicity of SBRT is more obvious than that of conventionally fractionated radiotherapy, but there is no significant difference in long-term toxicity. SBRT can provide more convenience for patients, and the medical cost is lower, so it has a great clinical application prospect.

Key words: Prostatic neoplasms, Radiosurgery, Radiotherapy

杜霄, 周菊英. 局限性前列腺癌的立体定向放疗[J]. 国际肿瘤学杂志, 2021, 48(5): 313-316.

Du Xiao, Zhou Juying. Stereotactic body radiotherapy for localized prostate cancer[J]. Journal of International Oncology, 2021, 48(5): 313-316.

参考文献 24

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020,70(1):7-30. DOI: 10.3322/caac.21590. doi: 10.3322/caac.v70.1
[2]	Bossi A, Blanchard P. Hypofractionation for prostate cancer: a word of caution[J]. Lancet Oncol, 2016,17(4):406-407. DOI: 10.1016/s1470-2045(15)00626-9. doi: 10.1016/S1470-2045(15)00626-9
[3]	Her EJ, Ebert MA, Kennedy AM, et al. Standard versus hypofractionated intensity-modulated radiotherapy for prostate cancer: asses-sing the impact on dose modulation and normal tissue effects when using patient-specific cancer biology[J]. Phys Med Biol, 2021,66(4):045007. DOI: 10.1088/1361-6560/ab9354. doi: 10.1088/1361-6560/ab9354
[4]	Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer[J]. N Engl J Med, 2016,375(15):1415-1424. DOI: 10.1056/NEJMoa1606220. doi: 10.1056/NEJMoa1606220
[5]	Musunuru HB, Quon H, Davidson M, et al. Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials[J]. Radiother Oncol, 2016,118(1):112-117. DOI: 10.1016/j.radonc.2015.12.020. doi: 10.1016/j.radonc.2015.12.020 pmid: 26796591
[6]	Kishan AU, Dang A, Katz AJ, et al. Long-term outcomes of ste-reotactic body radiotherapy for low-risk and intermediate-risk prostate cancer[J]. JAMA Netw Open, 2019,2(2):e188006. DOI: 10.1001/jamanetworkopen.2018.8006. doi: 10.1001/jamanetworkopen.2018.8006
[7]	Voong KR, Lal LS, Kuban DA, et al. Long-term economic value of hypofractionated prostate radiation: secondary analysis of a rando-mized trial[J]. Adv Radiat Oncol, 2017,2(3):249-258. DOI: 10.1016/j.adro.2017.07.010. doi: 10.1016/j.adro.2017.07.010 pmid: 29114589
[8]	Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?[J]. Int J Radiat Oncol Biol Phys, 2014,88(2):254-262. DOI: 10.1016/j.ijrobp.2013.07.022. doi: 10.1016/j.ijrobp.2013.07.022
[9]	Taguchi S, Shiraishi K, Fukuhara H. Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer[J]. Jpn J Clin Oncol, 2020,50(9):963-969. DOI: 10.1093/jjco/hyaa105. doi: 10.1093/jjco/hyaa105
[10]	Smolska-Ciszewska B, Miszczyk L, Bialas B, et al. The effectiveness and side effects of conformal external beam radiotherapy combined with high-dose-rate brachytherapy boost compared to conformal external beam radiotherapy alone in patients with prostate cancer[J]. Radiat Oncol, 2015,10:60. DOI: 10.1186/s13014-015-0366-z. doi: 10.1186/s13014-015-0366-z pmid: 25884489
[11]	刘跃平, 马建辉, 李晔雄. 前列腺癌的放射治疗[J]. 中华泌尿外科杂志, 2017,38(6):412-416. DOI: 10.3760/cma.j.issn.1000-6702.2017.06.004.
[12]	Lehrer EJ, Kishan AU, Yu JB, et al. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: a systematic review and meta-analysis of phase Ⅲ randomized trials[J]. Radiother Oncol, 2020,148:235-242. DOI: 10.1016/j.radonc.2020.04.037. doi: S0167-8140(20)30218-8 pmid: 32505965
[13]	Datta NR, Stutz E, Rogers S, et al. Clinical estimation of α/β va-lues for prostate cancer from isoeffective phase Ⅲ randomized trials with moderately hypofractionated radiotherapy[J]. Acta Oncol, 2018,57(7):883-894. DOI: 10.1080/0284186X.2018.1433874. doi: 10.1080/0284186X.2018.1433874
[14]	Adorno Febles VR, Blacksburg S, Haas JA, et al. Translating the immunobiology of SBRT to novel therapeutic combinations for advanced prostate cancer[J]. Front Oncol, 2020,10:830. DOI: 10.3389/fonc.2020.00830. doi: 10.3389/fonc.2020.00830
[15]	Proust-Lima C, Taylor JM, Secher S, et al. Confirmation of a low α/β ratio for prostate cancer treated by external beam radiation the-rapy alone using a post-treatment repeated-measures model for PSA dynamics[J]. Int J Radiat Oncol Biol Phys, 2011,79(1):195-201. DOI: 10.1016/j.ijrobp.2009.10.008. doi: 10.1016/j.ijrobp.2009.10.008
[16]	Vogelius IR, Bentzen SM. Meta-analysis of the α/β ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news?[J]. Int J Radiat Oncol Biol Phys, 2013,85(1):89-94. DOI: 10.1016/j.ijrobp.2012.03.004. doi: 10.1016/j.ijrobp.2012.03.004
[17]	Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial[J]. The Lancet, 2019,394(10196):385-395. DOI: 10.1016/s0140-6736(19)31131-6. doi: 10.1016/S0140-6736(19)31131-6
[18]	Alayed Y, Cheung P, Pang G, et al. Dose escalation for prostate stereotactic ablative radiotherapy (SABR): late outcomes from two prospective clinical trials[J]. Radiother Oncol, 2018,127(2):213-218. DOI: 10.1016/j.radonc.2018.03.005 doi: S0167-8140(18)30137-3 pmid: 29588072
[19]	Jackson WC, Silva J, Hartman HE, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies[J]. Int J Radiat Oncol Biol Phys, 2019,104(4):778-789. DOI: 10.1016/j.ijrobp.2019.03.051. doi: 10.1016/j.ijrobp.2019.03.051
[20]	Alayed Y, Cheung P, Vesprini D, et al. SABR in high-risk prostate cancer: outcomes from 2 prospective clinical trials with and without elective nodal irradiation[J]. Int J Radiat Oncol Biol Phys, 2019,104(1):36-41. DOI: 10.1016/j.ijrobp.2018.11.011. doi: 10.1016/j.ijrobp.2018.11.011
[21]	Quon HC, Musunuru HB, Cheung P, et al. Dose-escalated ste-reotactic body radiation therapy for prostate cancer: quality-of-life comparison of two prospective trials[J]. Front Oncol, 2016,6:185. DOI: 10.3389/fonc.2016.00185.
[22]	Kim DW, Cho LC, Straka C, et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer[J]. Int J Radiat Oncol Biol Phys, 2014,89(3):509-517. DOI: 10.1016/j.ijrobp.2014.03.012. doi: 10.1016/j.ijrobp.2014.03.012
[23]	Ito K, Kobayashi M, Komiyama M, et al. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial[J]. Cancer, 2020,126(17):3961-3971. DOI: 10.1002/cncr.33034. doi: 10.1002/cncr.v126.17
[24]	McKay RR, Feng FY, Wang AY, et al. Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions[J]. Am Soc Clin Oncol Educ Book, 2020,40:1-12. DOI: 10.1200/EDBK_279459. doi: 10.1200/EDBK_279459 pmid: 32412803